MedPath

Green3Bio, Inc.

Ownership
Private
Employees
-
Market Cap
-
Website

First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

Phase 1
Suspended
Conditions
Ovarian Tumors
Interventions
Drug: GRN-300
Drug: Paclitaxel
First Posted Date
2021-01-15
Last Posted Date
2024-01-23
Lead Sponsor
Green3Bio, Inc.
Target Recruit Count
73
Registration Number
NCT04711161
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath